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(155 days). CONCLUSIONS: Premixed insulin analogues were more frequently pre-
scribed by Dutch physicians than human premixed insulin. Users of premixed insulin 
analogues neither discontinued nor switched therapy as frequently as human premixed 
users, suggesting that premixed analogues gave a more sustained and satisfactory 
result.
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OBJECTIVES: To apply a risk assessment algorithm to a national US population 
sample (i) to determine the prevalence of at-risk pre-diabetic and undiagnosed diabetic 
participants and (ii) to validate the role of the risk factors included in the scoring 
algorithm in the prediction of diagnosed type 2 diabetes. METHODS: Data from the 
2009 US National Health and Wellness Survey (NHWS) were used to apply a modiﬁed 
version of a recently developed scoring algorithm/prediction model to identify patients 
at-risk for screening for pre-diabetes and undiagnosed diabetes. The algorithm com-
bines six risk factors to generate total risk scores: age, gender, family history of 
hypertension, high blood pressure, obesity, and physical activity. Estimates of the 
national prevalence of those at risk together with key health status attributes were 
generated. RESULTS: Among those 18 years of age and over in the NHWS sample 
(N = 74,474) without a conﬁrmed diagnosis of diabetes, 27.3% of participants were 
estimated to be at elevated risk for diabetes and a further 16.5% for pre-diabetes. 
Among those with a conﬁrmed diagnosis of diabetes (excluding persons with type 1 
diabetes), 73.6% were conﬁrmed by the scoring algorithm with a further 13.8% 
meeting pre-diabetic criteria. Overall, 10.0% had a conﬁrmed type 2 diabetes diag-
nosis. The ﬁtted prediction model indicated the following variables were strongest risk 
factors in the NHWS sample: i) age 60 years and over (odds ratio 6.94); ii) morbid 
obesity (odds ratio 6.11); iii) a family history of diabetes (odds ratio 4.79); and (iv) 
being obese (odds ratio 3.04). All variables signiﬁcant at the 1% level. The sensitivity 
was 23.2%, speciﬁcity 97.8%, positive predictive value 57.3% and negative predictive 
value 91.0%, with area under the ROC curve of 0.847. CONCLUSIONS: This study 
provides strong support for the new scoring algorithm to identify both pre-diabetic 
and diabetic at-risk populations.
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OBJECTIVES: Results of intervention studies in patients with type 2 diabetes have 
led to concerns about the safety of aiming for normal blood glucose concentrations. 
We assessed survival as a function of HbA1c in people with type 2 diabetes. 
METHODS: Two cohorts of patients aged 40 years and older with type 2 diabetes 
were generated from the THIN database of UK general practice records from 1986 
to 2008. Those with diabetes secondary to other causes were excluded. We identiﬁed 
37,626 and 22,769 patients commenced on metformin or sulphonylurea monotherapy 
respectively; 24,784 intensiﬁed from oral monotherapy to combination therapy with 
oral blood-glucose lowering agents; and 15,855 changed to regimens that included 
insulin. All-cause mortality was the primary outcome. Age, sex, smoking status, 
cholesterol, cardiovascular risk, and general morbidity were identiﬁed as important 
confounding factors, and Cox survival models were adjusted for these factors accord-
ingly. RESULTS: Compared to the HbA1c response category 7.0 to ≤7.5, those 
achieving the tightest glycaemic control (mean post-index HbA1c < 6.1%) had a 
substantially elevated adjusted hazard ratio for all-cause mortality (HR = 1.52 [95%CI 
1.39 to 1.66]), as did those with the poorest glycaemic control (HbA1c response > 
10%, HR 1.45 [1.30 to 1.63]). A ‘U-shaped’ association between glycaemic control 
and survival emerged in all treatment cohorts for which the adjusted HR in those 
achieving tightest glycaemic control (cf. referent) ranged from 1.44 (1.20 to 1.72) for 
metformin monotherapy to 2.61 [2.05 to 3.32] for the insulin-treated cohort. CON-
CLUSIONS: Low and high mean HbA1c values were associated with increased all-
cause mortality corroborating the ﬁndings of the ACCORD trial. Diabetes guidelines 
and current health economic models may need revision to reﬂect the safety implica-
tions of very tight glycaemic control in Type 2 diabetes.
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OBJECTIVES: Patients with type 2 diabetes are at increased risk for cardiovascular 
(CV) events. Whether agents that reduce hyperglycemia increase, decrease, or have no 
effect on CV outcomes is important. Comparative data among newer agents are 
limited. The study objective was to assess the relative incidence rate of CV events 
among patients prescribed exenatide, a GLP-1 receptor agonist, versus thiazolidinedio-
nes (TZDs). METHODS: Intent-to-treat analyses utilizing the LifeLink™ health plan 
claims database included patients initiating a new prescription for exenatide or a TZD 
between June 1, 2005, and March 31, 2009, and had no evidence of exenatide or 
TZD use in the prior 9 months. Patients were assigned to exenatide or TZD groups 
based on the ﬁrst new prescription. For the primary analysis, patients were followed 
until one of the following occurred: CV event (acute myocardial infarction, stroke, or 
coronary revascularization procedure), insurance disenrollment, or study end. Patient 
outcomes, adjusted for differences in clinical and demographic characteristics, were 
compared using person-time (Poisson regression) analyses. A secondary analysis of 
hospitalization rates was conducted. RESULTS: A total of 23,972 and 66,860 patients 
were assigned to exenatide and TZD therapies, respectively. Mean (SD) ages were 52 
(± 9.3) years (exenatide-treated) and 54 (± 10.8) years (TZD-treated). 41.9% of 
exenatide-treated patients and 53.9% of TZD-treated patients were male. Exenatide-
treated patients were more likely to have hyperlipidemia (63.4% vs. 55.0%) and 
hypertension (62.4% vs. 57.1%). Exenatide-treated patients were 17% less likely than 
TZD-treated patients to have a CV event (HR = 0.83; CI, 0.77–0.89; P < 0.0001). 
The exenatide group had signiﬁcantly lower rates of CV-related hospitalization (RR 
= 0.77; P < 0.0001). CONCLUSIONS: In this analysis of glucose-lowering therapies, 
exenatide treatment was associated with a lower risk of CV-related events compared 
to TZD treatment.
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OBJECTIVES: To study predictors of statin use in overweight and obese adults and 
consistency with current 2004 American Diabetes Association (ADA) guidelines. 
METHODS: A retrospective cross-sectional analysis of National Ambulatory Medical 
Care Survey (NAMCS) and outpatient part of the National Hospital Ambulatory 
Medical Care Survey (NHAMCS) of 2005–2007 was conducted among overweight 
and obese adults aged 18 to 64 years. Statin prescription (received or not) was the 
outcome measure. Descriptive statistics and multivariate logistic regression were 
carried using SAS9.2 to determine predictors of receiving statin prescriptions. The 
multivariate model was stratiﬁed based on age: Model1¬¬ (18 to 40years) and Model2 
(41 to 64years), as a signiﬁcant interaction was found between diabetes and age (chunk 
test p = 4.3729e-8). RESULTS: A total of 3141.387 million visits were examined, 
94.176 (2.99%) with a statin prescription. Diabetics were more likely to receive a 
statin prescription compared to nondiabetics [Model1: Odds Ratio (O.R.) 4.12 
(95%Conﬁdence Interval (C.I.): 2.77–6.12, p < 0.0001); Model2: O.R. 2.69 (95%C.I: 
2.21–3.27, p < 0.0001)]. Females were less likely to get statin prescription compared 
to males [Model1: O.R.0.52 (C.I. 0.42–0.63 p < 0.0001) Model2: O.R.0.68 (C.I. 
0.59–0.78 p < 0.0001)]. Specialists were more likely to prescribe statin compared to 
generalists [Model1: O.R. 1.44 (C.I:1.31–1.84, p = 0.0033); Model2: O.R. 1.61 (C.I: 
1.35–1.91, p < 0.0001)]. Other signiﬁcant predictors included hypertension (p1 = 
0.0037; p2 < 0.0001), hyperlipidemia (p1 < 0.0001; p2 < 0.0001), congestive heart 
failure (p1 = 0.0044; p2 < 0.0004) and counseling (p1 = 0.0011, p2 < 0.0001). Race 
and payment type were not signiﬁcantly associated. CONCLUSIONS: Diabetics were 
more likely to receive statin prescriptions compared to nondiabetics, consistent with 
ADA recommendations. Further research is needed to ensure achievement of target 
cholesterol levels in this high risk population.
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OBJECTIVES: A new dipeptidyl peptidase-4 inhibitor, saxagliptin, has been recently 
approved for the T2D treatment. This study evaluates the budget impact of the intro-
duction of saxagliptin to the Brazilian Private Healthcare System (PHS). METHODS: 
A model was developed to estimate the annual cost of T2D treatment per patient of 
the population potentially impacted by the introduction of saxagliptin to the PHS. 
The analysis also estimates the economic impact to the system of all oral anti-diabetic 
drugs (OADs) for 3 consecutive years. Target population (T2D patients on OADs and 
HbA1c uncontrolled) and patient distribution across therapeutic options are based on 
epidemiological and pharmacoepidemiological data, and clinical specialist interviews. 
Pharmaceutical direct costs are based on factory price (FP) and Deﬁned Daily Dose 
(DDD). We assumed saxagliptin FP to be 115.3% of sitagliptin FP. Univariate Deter-
ministic sensitivity analysis is conducted to determine the impact of parameters on 
results. RESULTS: The growth in population and prevalence increased the target 
population throughout the analysis. The prevalence estimate in year 1 was 328,218 
and increased to 349,212 in year 3. The growth also impacted total costs in scenario 
